NuvOx Therapeutics, Inc.

What the company does

NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing oxygen therapeutic solutions for diseases in which hypoxia plays a critical role. Its lead product candidate, NanO2, is an intravenously administered emulsified liquid containing nano-sized droplets that convert to gas and are designed to enhance oxygen delivery. Clinical research has focused on acute ischemic stroke, glioblastoma multiforme, acute respiratory distress syndrome, and sickle cell anemia.

Use of proceeds

The company expects to use the net proceeds to fund completion of clinical trials for glioblastoma multiforme, stroke, and acute respiratory distress syndrome, prepare for a Phase III glioblastoma multiforme trial, fund a Phase II acute respiratory distress syndrome trial, and fund ongoing product development and working capital.

Underwriters

Extracted from S-1/A 0001213900-26-113463, filed Oct 29, 2026 and verified against that filing text.

Key risk factors

• Limited operating history

  “We are a development-stage company with a limited operating history;”

• No approved commercial products

  “We have no products approved for commercial sales and a limited operating history upon which to evaluate our ability to commercialize our product candidate;”

• Continuing operating losses

  “We have a history of operating losses and expect to continue to incur substantial losses for the foreseeable future;”

• Going-concern uncertainty

  “Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern;”

• Limited funding runway

  “Our cash and the proceeds of this offering will only fund our operations for a limited time, and we will need to raise additional capital to fund our planned clinical trials and development and commercialization efforts;”

• Dependence on NanO2

  “Our business is dependent upon the success of NanO2, which requires additional clinical testing before we can seek regulatory approval;”

• Regulatory approval uncertainty

  “Our efforts to develop our product candidate may not generate data sufficient to support an application for regulatory approval and even if we complete our clinical trials, we may not receive regulatory approval for NanO2;”

• Clinical trial delays

  “We may experience delays in the enrollment of patients in any of our clinical trials;”